MedPath

Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach

Completed
Conditions
Covid19
Cancer
Solid Tumor
Interventions
Other: COCA is an observational study based on retrospective data issued from patient medial file.
Registration Number
NCT04910633
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

An article to present how cancer patients were taken in charge at Lyon University Hospital Cancer Institute (France) during the first peak of the COVID-19 pandemic between March and May 2020 is under writing.

It will present strategies that were set-up to avoid cross-contamination between patients and caregivers, patients treatment adaptation (timing, dosage,..) and how consultations, multidisciplinary team meetings, surgical procedures and clinical trials were impacted.

Part of this article will also illustrate the characteristics of patients with a solid tumor(s) that have been hospitalized during this timeframe for the COVID-19. How cancer type and stage affect Covid severity and mortality.will be described for a small sample of patients (44). These qualitative figures will be compared to literature current state of the art.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Patients with a LUHCI code created after 2015 and a LUHCI COVID-19 code created between March 2020 and May 2020.
Read More
Exclusion Criteria
  • Patients who did not allow the reuse of their medical file data for research related to COVID-19-
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Solid Tumor and COVID-19COCA is an observational study based on retrospective data issued from patient medial file.Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
Primary Outcome Measures
NameTimeMethod
Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age.At the end of Month 1

COVID-19 severity will be determined based on chest X-Ray damage as follow. Low severity : ≤25% of chest X-Ray damage, Middle severity: between 25-50% of chest X-Ray damage, High Severity : above 50% of chest X-Ray damage.

A graphic will then be drafted to present the relationship between Covid-19 severity depending on patient age, cancer nature, and cancer stage.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Lyon University Hospital Cancer Institute

🇫🇷

Bron, France

© Copyright 2025. All Rights Reserved by MedPath